Today: 29 June 2026
Browse Category

NASDAQ:BHVN 14 August 2025 - 5 November 2025

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.
5 November 2025
·
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···

Stock Market Today

  • AMD Shares Dip Below Wall Street Targets Amid Semiconductor Sector Selloff
    June 28, 2026, 6:22 PM EDT. Advanced Micro Devices (AMD) shares fell 2.06% to $521.58 on June 26, with trading volume 39% above the 65-day average, reflecting a broader chip sector selloff. AMD's stock is down 5.4% since Monday and trades 7.4% below its 52-week high. The average analyst price target is $502.92, below current levels, while the top estimate stands at $670. Semiconductor peers Nvidia and Intel also declined sharply, pushing the PHLX chip index down 5.3% for the day and 7.9% for the week. UBS analyst Timothy Arcuri maintains a bullish outlook, increasing AMD's target to $670 based on projected CPU server revenue growth through 2030, despite ongoing concerns over AI spending and market inflation pressures in memory prices.

Latest articles

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Go toTop